AMGN
Amgen Inc. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow +9.4% ·
net new positions -10.0%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.52M | $603.13M | n/a | −2 |
| Q2 2026 | 169 | -1 | 364.70M | $131.99B | +5 | −7 |
| Q1 2026 | 174 | -2 | 366.40M | $128.82B | +4 | −7 |
| Q4 2025 | 175 | 0 | 394.29M | $128.98B | +2 | −1 |
| Q3 2025 | 26 | 0 | 206.42M | $58.23B | n/a | −1 |
| Q2 2025 | 24 | +1 | 183.25M | $51.15B | +2 | −1 |
| Q1 2025 | 20 | -2 | 81.79M | $25.47B | n/a | −2 |
| Q4 2024 | 22 | +2 | 74.78M | $19.48B | +2 | n/a |
| Q3 2024 | 19 | -1 | 39.65M | $12.76B | +1 | −2 |
| Q2 2024 | 20 | n/a | 39.58M | $12.36B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 29.18M | -0.9% | $9.09B | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 2 | Capital World Investors ✦ | 16.70M | +157.1% | $5.20B | 0.8% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 12.73M | +2.0% | $3.95B | 0.3% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | PRIMECAP Management ✦ | 12.39M | -4.7% | $3.86B | 3.2% | ▼ Trim | 4 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 5.65M | -4.5% | $1.76B | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 2.04M | -22.9% | $634.81M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 1.26M | -36.1% | $392.83M | 0.5% | ▼ Trim | 4 | SEC ↗ ×2 |
| 8 | Fisher Asset Management ✦ | 437.82K | +11.0% | $136.40M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 359.52K | -60.1% | $112.01M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 257.16K | -12.4% | $80.12M | 0.0% | ▼ Trim | 4 | SEC ↗ ×8 |
| 11 | Adage Capital Partners ✦ | 225.87K | -25.9% | $70.37M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 12 | Marshall Wace ✦ | 178.26K | +2836.2% | $55.54M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 13 | Renaissance Technologies ✦ | 114.40K | +65.7% | $35.64M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 91.49K | +103.0% | $28.32M | 0.0% | ▲ Add | 4 | SEC ↗ ×6 |
| 15 | ARK Investment Management ✦ | 59.03K | -11.1% | $18.39M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 16 | Millennium Management ✦ | 50.32K | -67.4% | $15.68M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 25.56K | +17.6% | $7.96M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 20.00K | -96.2% | $6.23M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Dodge & Cox ✦ | 13.53K | -5.2% | $4.22M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | GAMCO Investors ✦ | 4.54K | -13.9% | $1.42M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Arrowstreet Capital | $8.80M | was 0.0% |
| Bridgewater Associates | $368,806 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 3,100 holders, 420.54M shares, $144.29B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.25K sh · $521,365
Officer · 2.00K sh · $825,134
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology